Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert V. Market is active.

Publication


Featured researches published by Robert V. Market.


Carbohydrate Research | 1999

Stereospecific α-d-mannosylation

Ian L. Scott; Robert V. Market; Russell Joseph Deorazio; Harold Meckler; Timothy P. Kogan

Abstract The stereospecific formation of α- d -mannosyl glycosidic linkages has been achieved in high yield using tetra- O -pivaloyl-α- d -mannopyranosyl fluoride and boron trifluoride diethyl etherate in dichloromethane. Examples of the α- d -mannosylation of primary, secondary, benzylic and phenolic hydroxyl groups are described.


Scientific Reports | 2018

Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1

Darren G. Woodside; Eric A. Tanifum; Ketan B. Ghaghada; Ronald J. Biediger; Amy R. Caivano; Zbigniew Starosolski; Sayadeth Khounlo; Saakshi Bhayana; Shahrzad Abbasi; John W. Craft; David Maxwell; Chandreshkumar Patel; Igor Stupin; Deenadayalan Bakthavatsalam; Robert V. Market; James T. Willerson; Richard A. F. Dixon; Peter Vanderslice; Ananth Annapragada

Inflammation drives the degradation of atherosclerotic plaque, yet there are no non-invasive techniques available for imaging overall inflammation in atherosclerotic plaques, especially in the coronary arteries. To address this, we have developed a clinically relevant system to image overall inflammatory cell burden in plaque. Here, we describe a targeted contrast agent (THI0567-targeted liposomal-Gd) that is suitable for magnetic resonance (MR) imaging and binds with high affinity and selectivity to the integrin α4β1(very late antigen-4, VLA-4), a key integrin involved in recruiting inflammatory cells to atherosclerotic plaques. This liposomal contrast agent has a high T1 relaxivity (~2 × 105 mM−1s−1 on a particle basis) resulting in the ability to image liposomes at a clinically relevant MR field strength. We were able to visualize atherosclerotic plaques in various regions of the aorta in atherosclerosis-prone ApoE−/− mice on a 1 Tesla small animal MRI scanner. These enhanced signals corresponded to the accumulation of monocyte/macrophages in the subendothelial layer of atherosclerotic plaques in vivo, whereas non-targeted liposomal nanoparticles did not demonstrate comparable signal enhancement. An inflammatory cell-targeted method that has the specificity and sensitivity to measure the inflammatory burden of a plaque could be used to noninvasively identify patients at risk of an acute ischemic event.


Journal of Medicinal Chemistry | 1995

Rational Design and Synthesis of Small Molecule, Non-oligosaccharide Selectin Inhibitors: (.alpha.-D-Mannopyranosyloxy)biphenyl-Substituted Carboxylic Acids

Timothy P. Kogan; Brian Dupre; Karin Keller; Ian L. Scott; Huong Bui; Robert V. Market; Pamela J. Beck; J. A. Voytus; B. M. Revelle; D. Scott


Archive | 2001

Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Ronald J. Biediger; Qi Chen; E. Radford Decker; George W. Holland; Jamal M. Kassir; Wen Li; Robert V. Market; Ian L. Scott; Chengde Wu; Jian Li


Archive | 2004

Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists

Chengde Wu; Eric C. Anderson; Huong Bui; Daxin Gao; Jamal M. Kassir; Wen Li; Junmei Wang; Robert V. Market


Archive | 1999

N,n-disubstituted amides that inhibit the binding of integrins to their receptors

Jamal M. Kassir; Ronald J. Biediger; Vanessa O. Grabbe; Shuqun Lin; Robert V. Market; Bore Gowda Raju; Ian L. Scott; Timothy P. Kogan


Archive | 1999

Compounds that inhibit the binding of integrins to their receptors

Ronald J. Biediger; Vanessa O. Grabbe; George W. Holland; Jamal M. Kassir; Karin Keller; Timothy P. Kogan; Shuqun Lin; Robert V. Market; Bore Gowda Raju; Ian L. Scott; Chengde Wu


Journal of Medicinal Chemistry | 1999

Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors1

Chengde Wu; E. Radford Decker; Natalie Blok; Huong Bui; Qi Chen; Bore Gowda Raju; Andree R. Bourgoyne; Vippra Knowles; Ronald J. Biediger; Robert V. Market; Shuqun Lin; Brian Dupre; Timothy P. Kogan; George W. Holland; and Tommy A. Brock; Richard A. Dixon


Archive | 1998

Compounds that inhibit the binding of vascular endothelial growth factor to its receptors

Ian L. Scott; Ronald J. Biediger; Robert V. Market


Archive | 2008

Modulators of ccr9 receptor and methods of use thereof

Eric C. Anderson; Ronald J. Biediger; Jie Chen; Brian Dupre; Pedro Lory; Robert V. Market; Keith A. Monk; Michael M. Savage; Reginald Tennyson; Brandon M. Young

Collaboration


Dive into the Robert V. Market's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ian L. Scott

Albany Molecular Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Junmei Wang

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pamela J. Beck

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amy R. Caivano

The Texas Heart Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge